Myofascial trigger points: Translating molecular theory into manual therapy

Journal of Manual and Manipulative Therapy

Volumn 14, Issue 4, 2006, Pages 232-239

  McPartland, John M ^a   Simons, David G ^a  

^a NONE

Author keywords

Acetycholine Receptor; Acetylcholinesterase; Motor Endplate; Myofascial Trigger Points

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ADENOSINE TRIPHOSPHATE; NICOTINIC RECEPTOR;

ACETYLCHOLINE RELEASE; DEPOLARIZATION; ELECTRIC POTENTIAL; HUMAN; HYPOTHESIS; MANIPULATIVE MEDICINE; MUSCLE CONTRACTION; MUSCLE POTENTIAL; MYOFASCIAL PAIN; NERVE ENDING; PATHOPHYSIOLOGY; REVIEW; SENSITIZATION; THEORY;

EID: 33846227571     PISSN: 10669817     EISSN: None     Source Type: Journal    
DOI: 10.1179/106698106790819982     Document Type: Review

References (64)

1. nd ed. Baltimore, MD: Williams & Wilkins, 1999.
2. Simons, DG. Clinical and etiological update of myofascial pain from trigger points. J Musculoskel Pain 1996;4:97-125.
3. Hubbard DR, Berkoff GM. Myofascial trigger points show spontaneous needle EMG activity. Spine 1993;18:1803-1807.
4. Liley AW. An investigation of spontaneous activity at the neuromuscular junction of the rat J Physiology (Lond) 1956;132:650-666.
5. Simons DG. Review of enigmatic MTrPs as a common cause of enigmatic musculoskeletal pain and dysfunction. J Electromyog Kinesiol 2004;14:95-107.
6. Kuan TS, Chen JT, Chen SM, Chien CH, Hong CZ. Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle. Am J Phys Med Rehabil 2002;81:512-520.
7. Mense S, Simons DG, Hoheisel U, Quenzer B. Lesions of rat skeletal muscle after local block of acetylcholinesterase and neuromuscular stimulation. J Appl Physiol 2003;94:2494-2501.
8. Chen BM, Grinnell AD. Kinetics, Ca2+ dependence, and biophysical properties of integrin-mediated mechanical modulation of transmitter release from frog motor nerve terminals. J Neurosci 1997;17:904-916.
9. McPartland JM. Travell trigger points: Molecular and osteopathic perspectives. J Amer Osteopathic Assoc 2002;104:244-249.
10. Grisaru D, Sternfeld M, Eldor A, Glick D, Soreq H. Structural roles of acetylcholinesterase variants in biology and pathology. Eur J Biochem 1999;264:672-686.
11. Wecker L, Mrak RE, Dettbarn WD. Evidence of necrosis in human intercostal muscle following inhalation of an organophosphate insecticide. Fundam Appl Toxicol 1986;6:172-174.
12. De Bleecker JL, Meire VI, Pappens S. Quinidine prevents paraoxon-induced necrotizing myopathy in rats. Neurotoxicology 1998;19:833-838.
13. Meshul CK. Calcium channel blocker reverses anticholinesterase-induced myopathy. Brain Res 1989;497:142-148.
14. Zhou M, Engel AG, Auerbach A. Serum choline activates mutant acetylcholine receptors that cause slow channel congenital myasthenic syndromes. Proc Natl Acad Sci U S A 1999;96:10466-10471.
15. Shen XM, Ohno K, Sine SM, Engel AG. Subunit-specific contribution to agonist binding and channel gating revealed by inherited mutation in muscle acetylcholine receptor M3-M4 linker. Brain 2005;128:345-355.
16. Gentry CL, Lukas RJ. Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes. J Pharmacol Exp Ther 2001;299:1038-1048.
17. Wang X, Li Y, Engisch KL, Nakanishi ST, Dodson SE, Miller GW, Cope TC, Pinter MJ, Rich MM. Activity-dependent presynaptic regulation of quantal size at the mammalian neuromuscular junction in vivo. J Neurosci 2005;25:343-351.
18. Nakanishi ST, Cope TC, Rich MM, Carrasco DI, Pinter MJ. Regulation of motoneuron excitability via motor endplate acetylcholine receptor activation. J Neurosci 2005;25:2226-2232.
19. Mense S, Simons DG. Muscle Pain: Understanding its Nature, Diagnosis, and Treatment. Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
20. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999;92:1171-1175.
21. Gessa GL, Casu MA, Carta G, Mascia MS. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus. Eur J Pharmacol 1998;355:119-124.
22. Giniatullin RA, Sokolova EM. ATP and adenosine inhibit transmitter release at the frog neuromuscular junction through distinct presynaptic receptors. Br J Pharmacol 1998;124:839-844.
23. Silinsky EM. Adenosine decreases both presynaptic calcium currents and neurotransmitter release at the mouse neuromuscular junction. J Physiol 2004;558:389-401.
24. Oliveira L, Timoteo MA, Correia-de-Sa P. Tetanic depression is overcome by tonic adenosine A(2A) receptor facilitation of L-type Ca(2+) influx into rat motor nerve terminals. J Physiol 2004;560:157-168.
25. Headly BJ. The use of biofeedback in pain management. Physical Therapy Practice 1993;2(2):29-40.
26. Headly BJ. Evaluation and treatment of myofascial pain syndrome utilizing biofeedback. In: Cram JR, ed. Clinical Electromyography for Surface Recordings. Vol. 2. Nevada City, NV: Clinical Resources, 1990:235-254.
27. Headly BJ. Chronic pain management. In: O'Sullivan SB, Schmitz TS, eds. Physical Rehabilitation: Assessment and Treatment. Philadelphia, PA: F.A. Davis Co., 1994:577-600.
28. Butler DS. The Sensitive Nervous System. Adelaide, Australia: Noigroup Publications, 2000.
29. Shah JP, Phillips TM, Danoff JV, Gerber LH. An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol 2005;99:1977-1984
30. Korr IM. The spinal cord as organizer of disease processes. In: Peterson B, ed. The Collected Papers of Irvin M. Korr. Newark, OH: American Academy of Osteopathy, 1979:207-221.
31. Roatta S, Windhorst U, Ljubisavljevic M, Johansson H, Passatore M. Sympathetic modulation of muscle spindle afferent sensitivity to stretch in rabbit jaw closing muscles. J Physiol 2002;540:237-248.
32. Bukharaeva EA, Gainulov RKh, Nikol'skii EE. The effects of noradrenaline on the amplitude-time characteristics of multiquantum endplate currents and the kinetics of induced secretion of transmitter quanta. Neurosci Behav Physiol 2002;32:549-554.
33. Chen JT, Chen SM, Kuan TS, Chung KC, Hong CZ. Phentolamine effect on the spontaneous electrical activity of active loci in a myofascial trigger spot of rabbit skeletal muscle. Arch Phys Med Rehabil 1998;79:790-794.
34. Rivner MH. The neurophysiology of myofascial pain syndrome. Curr Pain Headache Rep 2001;5:432-440.
35. nd ed. Baltimore, MD: Williams & Wilkins, 2002:1034-1050.
36. Lewit K. Chain reactions in disturbed function of the motor system. Manual Medicine 1987;3:27-29.
37. nd ed. Oxford, UK: Butterworth Heinemann, 1991.
38. McPartland JM, Brodeur R, Hallgren RC. Chronic neck pain, standing balance, and suboccipital muscle atrophy. J Manipulative Physiol Ther 1997;21:24-29.
39. Peck D, Buxton DF, Nitz A. A comparison of spindle concentrations in large and small muscles acting in parallel combinations. J Morphology 1984;180:243-252.
40. Foldes FF, Kuze S, Vizi ES, Deery A. The influence of temperature on neuromuscular performance. J Neural Transm 1978;43:27-45.
41. McPartland JM, Mitchell J. Caffeine and chronic back pain. Arch Phys Med Rehab 1997;78:61-63.
42. Hsu KS, Kang JJ, Lin-Shiau SY. Muscle contracture and twitch depression induced by arsenite in the mouse phrenic nerve-diaphragm. Jpn J Pharmacol 1993;62:161-168.
43. Katsura M, Mohri Y, Shuto K, Hai-Du Y, Amano T, Tsujimura A, Sasa M, Ohkuma S. Up-regulation of L-type voltage-dependent calcium channels after long-term exposure to nicotine in cerebral cortical neurons. J Biol Chem 2002;277:7979-7988.
44. Yu J, Lu G, Xu J. [The effects of ethanol on neuromuscular junctions of adult toad.] Hua Xi Yi Ke Da Xue Xue Bao 2001;32:274-276.
45. Gerwin R, Gevirtz R. Chronic myofascial pain: Iron insufficiency and coldness as risk factors. J Musculoskel Pain 1995;3(Suppl 1):120 [abstract].
46. Brückle W, Suckfüll M, Fleckenstein W, Weiss C, Müller W. Gewebe-pO2-Messung in der verspannten Rückenmuskulatur (m. erector spinae) [Tissue pO2 measurement in hypertonic back muscles]. Z Rheumatol 1990;49:208-216.
47. Starlanyl D, Copeland M. Fibromyalgia and Chronic Myofascial Pain Syndrome: A Survival Manual. Oakland, CA: New Harbinger Publications Inc, 1996.
48. Berger J. Vermont DO urges peers to learn about herbal medicine. The DO 1999;40(3):58-60.
49. Re L, Barocci S, Sonnino S, Mencarelli A, Vivani C, Paolucci G, Scarpantonio A, Rinaldi L, Mosca E. Linalool modifies the nicotinic receptor-ion channel kinetics at the mouse neuromuscular junction. Pharmacol Res 2000;42:177-182.
50. McPartland JM, Pruitt PP. Side effects of pharmaceuticals not elicited by comparable herbal medicines: The case of tetrahydrocannabinol and marijuana. Alternative Therapies Health Medicine 1999;5(4):57-62.
51. Barnes MP. Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006;7:607-615.
52. McPartland JM, Giuffrida A, King J, Skinner E, Scotter J, Musty RE. Cannabimimetic effects of osteopathic manipulative treatment. J Amer Osteopathic Assoc 2005;105:283-291.
53. Vernon HT, Dhami MS, Howley TP, Annett R. Spinal manipulation and beta-endorphin: A controlled study of the effect of a spinal manipulation on plasma beta-endorphin levels in normal males. J Manipulative Physiol Ther 1986;9:115-123.
54. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994;59:65-69.
55. Taguchi K, Shiina M, Shibata K, Utsunomiya I, Miyatake T. Spontaneous muscle action potentials are blocked by N-type and P/Q-calcium channels blockers in the rat spinal cord-muscle coculture system. Brain Res 2005;1034:62-70.
56. Hou CR, Chung KC, Chen JT, Hong CZ. Effects of a calcium channel blocker on electrical activity in myofascial trigger spots of rabbits. Am J Phys Med Rehabil 2002;81:342-349.
57. Sharifullina ER, Afzalov RA, Talantova MV, Vyskochil F, Giniatullin RA. Pre- and postsynaptic effects of the calcium channel blocker verapamil at neuromuscular junctions. Neurosci Behav Physiol 2002;32:309-315.
58. Piriz J, Rosato Siri MD, Pagani R, Uchitel OD. Nifedipine-mediated mobilization of intracellular calcium stores increases spontaneous neurotransmitter release at neonatal rat motor nerve terminals. J Pharmacol Exp Ther 2003;306:658-663.
59. Ferrante FM, Bearn L, Rothrock R, King L. Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A. Anesthesiology 2005;103:377-383.
60. Dalpiaz AS, Dodds TA. Myofascial pain response to topical lidocaine patch therapy: A case report. J Pain Palliat Care Pharmacoth 2002;16:99-104.
61. Gentry CL, Lukas RJ. Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes. J Pharmacol Exp Ther 2001;299:1038-1048.
62. McPartland JM. Use of capsaicin cream for abdominal wall scar pain. Am Fam Phys 2002;65:2211-2212.
63. McPartland JM, Pruitt PL. Sourcing the code: Searching for the evolutionary origins of cannabinoid receptors, vanilloid receptors, and anandamide. J Canna Therapeut 2002;2:73-103.
64. McMakin Cr, Gregory WM, Phillips TM. Cytokine changes with microcurrent treatment of fibromyalgia associated with cervical spine trauma. J Bodywork Movement Ther 2005;9:169-176.